Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors
AssigneeNeurogen Corporation
InventorsPing Ge, Raymond F. Horvath, Stephane De Lombaert
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of the formula: wherein Ar, Q1, Q2, R1, W and X are substituents as defined herein, which compounds are water-soluble CRF1 receptor antagonists, and are therefore useful for the treatment of psychiatric disorders and neurological diseases, including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
Claims15
A compound of the formula:
- or a pharmaceutically acceptable salt thereof wherein
- Q1 represents hydrogen, methyl, or ethyl;
- R25 represents a group of the formula
- where
- Rx represents hydrogen, methyl, ethyl;
- Ry represents hydrogen, methyl or ethyl;
- or NRxRy represents pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, or 4-(C1-C6 alkyl)piperazinyl.
4-Piperazinyl-3,6-dimethyl-1-(2,4,6-trimethylphenyl)pyrrolo[2,3-b]pyridine.
Dependencies are inferred from the claim text.